Launch Therapeutics Selects Medidata AI Intelligent Trials
Partnership optimizes trial planning and efficiency.
Medidata has announced that Launch Therapeutics (Launch Tx) selected Medidata AI Intelligent Trials to support its approach to accelerating clinical trials of late-stage therapies.
Medidata AI Intelligent Trials’ Study Feasibility solution provides Launch Tx with higher assurance that trial planning will improve enrollment and quality. This is done by leveraging country and site-level performance data, and predictive analytics. It’s built on a foundation of data from more than 30,000 clinical trials across a wide array of disease indications representing more than nine million study participants.
Reference
Launch Therapeutics Selects Medidata AI Intelligent Trials to Accelerate Clinical Trial Development. (2023, April 12). Medidata.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
